Status:
RECRUITING
Biomarkers of aHSCT
Lead Sponsor:
Sheffield Teaching Hospitals NHS Foundation Trust
Collaborating Sponsors:
Sheffield Hospitals Charity
Nottingham Trent University
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
16+ years
Brief Summary
The underlying disease mechanisms which occur in patients with immune mediation neurological diseases, such as Multiple Sclerosis (MS), are incompletely understood. For such patients, autologous haema...
Eligibility Criteria
Inclusion
- Diagnosis of a immune mediated neurological disease according to disease specific criteria (active treatment arm) or diagnosis of relapsing remitting multiple sclerosis (control arm).
- Treatment with autologous haematopoetic stem cell transplantation (active treatment arm) or high efficacy disease modifying treatment (control arm).
- Willing to provide biological samples for analysis and undergo clinical assessments for the duration of follow up.
- Able to understand English and provide informed consent.
Exclusion
- 1\. Inability to provide informed consent.
Key Trial Info
Start Date :
August 9 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 9 2026
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06195800
Start Date
August 9 2023
End Date
August 9 2026
Last Update
January 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, England, United Kingdom, S10 2JF